申请人:GlaxoSmithKline LLC
公开号:US20140378456A1
公开(公告)日:2014-12-25
This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.
本发明涉及苯并咪唑衍生物的使用,用于调节磷脂酰肌醇3′ OH激酶家族(以下简称PI3激酶)的活性或功能,特别是抑制其活性或功能,适当地,PI3Kα、PI3Kδ、PI3Kβ和/或PI3Kγ。适当地,本发明涉及苯并咪唑在治疗以下一种或多种疾病状态中的使用:自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官衰竭、肾脏疾病、血小板聚集、癌症、精子运动能力、移植排斥、移植物排斥和肺部损伤。更适当地,本发明涉及PI3Kβ选择性苯并咪唑化合物用于治疗癌症。